Ligand Pharmaceuticals (LGND) Current Assets (2010 - 2026)

Ligand Pharmaceuticals has disclosed Current Assets across 17 years of filings, most recently posting $865.4 million for Q1 2026.

• Current Assets for Q1 2026 came in at $865.4 million, up 179.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $865.4 million (up 179.78% YoY), and the FY2025 annual result was $832.3 million, up 151.02% from the prior year.
• Current Assets came in at $865.4 million for Q1 2026 at Ligand Pharmaceuticals, up from $832.3 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $865.4 million in Q1 2026 to a low of $220.4 million in Q3 2022.
• The 5-year median for Current Assets is $309.4 million (2024), against an average of $384.5 million.
• Across the five-year window, Current Assets sank 48.98% in 2022 and soared 179.78% in 2026, its largest moves.
• Ligand Pharmaceuticals' Current Assets stood at $263.6 million in 2022, then retreated by 9.93% to $237.4 million in 2023, then soared by 39.65% to $331.6 million in 2024, then soared by 151.02% to $832.3 million in 2025, then increased by 3.98% to $865.4 million in 2026.
• The last three Current Assets figures came in at $865.4 million (Q1 2026), $832.3 million (Q4 2025), and $753.9 million (Q3 2025), per Business Quant data.